1. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older
- Author
-
Tarik Asselah, Yang Lei, Sarah Kopecky-Bromberg, Federico J. Mensa, Roger Trinh, Neddie Zadeikis, Armen Asatryan, and Graham R. Foster
- Subjects
RNA viruses ,Cyclopropanes ,Male ,Aminoisobutyric Acids ,Pyrrolidines ,Hepacivirus ,Kidney ,Geriatric Depression ,Elderly ,0302 clinical medicine ,Medicine and Health Sciences ,030212 general & internal medicine ,Pathology and laboratory medicine ,Geriatric Nephrology ,Geriatrics ,Sulfonamides ,education.field_of_study ,Multidisciplinary ,Hepatitis C virus ,Depression ,Liver Diseases ,Hepatitis C ,Medical microbiology ,Pibrentasvir ,Treatment Outcome ,Cirrhosis ,Nephrology ,Viruses ,Medicine ,Drug Therapy, Combination ,Female ,030211 gastroenterology & hepatology ,Pathogens ,Research Article ,medicine.medical_specialty ,Drug Research and Development ,Proline ,Science ,Lactams, Macrocyclic ,Geriatric Psychiatry ,Population ,Gastroenterology and Hepatology ,Research and Analysis Methods ,Microbiology ,03 medical and health sciences ,Leucine ,Quinoxalines ,Internal medicine ,Mental Health and Psychiatry ,medicine ,Humans ,Clinical Trials ,education ,Adverse effect ,Aged ,Pharmacology ,Polypharmacy ,Biology and life sciences ,Flaviviruses ,Mood Disorders ,business.industry ,Organisms ,Viral pathogens ,Glecaprevir ,Hepatitis C, Chronic ,medicine.disease ,Fibrosis ,Hepatitis viruses ,Microbial pathogens ,Discontinuation ,Age Groups ,People and Places ,Population Groupings ,Benzimidazoles ,Clinical Medicine ,Safety Studies ,business ,Developmental Biology - Abstract
Finding safe and effective treatments for chronic hepatitis C virus (HCV) infection in the elderly is of clinical interest given the comorbidities and associated polypharmacy in this population. However, the number of patients older than age 65 years enrolled into clinical trials of anti-HCV medications generally have been limited and thus reaching meaningful conclusions for this demographic has been difficult. Glecaprevir/pibrentasvir is a once-daily, all-oral, ribavirin-free, pangenotypic direct-acting antiviral (DAA) combination therapy that has demonstrated high sustained virologic response rates at post-treatment week 12 (SVR12) and a favorable safety profile in patients with chronic HCV infection. This analysis evaluated the safety and efficacy of glecaprevir/pibrentasvir in patients aged ≥65 years. Data were pooled for treatment-naïve and -experienced patients with chronic HCV genotype (GT) 1-6 infections who received glecaprevir/pibrentasvir for 8, 12, or 16 weeks in 9 Phase 2 and 3 trials. SVR12 and adverse events (AEs) were evaluated for patients aged ≥65 versus
- Published
- 2019